ARWR

Arrowhead Pharmaceuticals develops experimental medicines using a technology called RNAi, which works by silencing specific genes that cause disease. The company is testing treatments for rare and difficult-to-treat conditions affecting the liver, heart, and metabolic systems. Most of their drugs are still in early-stage clinical trials, meaning they are being tested in patients but are not yet approved by regulators. Arrowhead partners with larger pharmaceutical companies like Glaxo Smith Kline, Takeda, and Amgen to help develop and commercialize these medicines.